Investor Presentation March 2016

NASDAQ:CEMI

Rapid Tests for Earlier Treatment™™

Slide 2

Forward Looking Statements

Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.  Those statements include statements regarding the intent, belief or current expectations of Chembio and its management. Such statements reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, Chembio's ability to develop, manufacture, market and finance new products and the demand for Chembio's products.  Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Other factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Slide 3

Investment Highlights

§ A global leader in point-of-care (POC) infectious disease

– Sales in 40+ countries, including United States

§ Revenue growth

– 8% CAGR over last five years (2010-2015)

§ Groundbreaking DPP^® technology platform

– Superior sensitivity and specificity vs lateral flow technology

– Multiple tests from a single oral fluid or blood sample

§ Robust pipeline of new DPP^® POC assays in development

– DPP^® HIV-Syphilis Combination Assay (U.S. version)

– DPP^® Fever Assays (Malaria, Dengue, Zika, Chikungunya, Ebola, Lassa, Marburg)

– DPP^® Technology Collaboration (Traumatic Brain Injury, Cancer and Micro Reader)

§ Multiple high-value collaborations

– Paul G. Allen Ebola Program: Fever Panel

– Paul G. Allen Family Foundation: Zika

– Centers for Disease Control & Prevention (CDC): Malaria, Ebola, Flu Immunostatus

Slide 4

Chembio's Dual Path Platform (DPP^®) Technology Next-Generation Point-of-Care Technology Platform

§ Patented POC technology platform

§ Improved sensitivity vs. lateral flow technology

§ Multiple test results from a single patient sample

§ Adapts to multiple sample types (blood, oral fluid)

§ Application across a range of diseases and markets

§ Unique sample collection device: Sampletainer^®

See graphics

Slide 5

Chembio's Dual Path Platform (DPP^®) Technology

Leveraging Our Technology Platform to Enter New Markets

Three areas of Strategic Focus:

· STD Business

· Fever Portfolio

· Technology Collaborations

DPP® Technology Platform

Slide 6

HIV Continues to be a Global Health Crisis Syphilis and HIV-Syphilis Co-Infection are Increasing

United States (HIV)

· ~ 1.2 million living with HIV/AIDS

· ~ 50,000 new HIV infections/year

· 1 in 8 unaware of HIV infection

Global (HIV)

· 35.2 million living with HIV/AIDS (2012)

· 1.6 million died of AIDS-related illnesses (2012)

United States (SYP)

· ~56,000 new infections (2013)

Global (SYP)

· 12 million new infections/year

"Over the past decade, the number of people living with HIV has increased, while the annual number of new HIV infections has remained relatively stable."  -CDC

"About 30% of pregnant women with syphilis will give birth to a dead baby (stillbirth), and another 30% to a live baby with congenital syphilis, a condition with a mortality of up to 50%"  -WHO

Slide 7

Product Portfolio: Sexually Transmitted Diseases

· DPP® HIV-Syphilis Combination

· DPP® HIV 1/2 Blood or Oral Fluid

· HIV 1/2 STAT-PAK®

· SURE CHECK® HIV 1/2

See graphics

Slide 8

Chembio Lateral Flow HIV Tests,  Foundational HIV Product Suite

Product Features & Benefits

· FDA (PMA) approved, CLIA-waived

· CE marked, WHO pre-qualified

· 2.5 - 5.0 μL blood sample

· 15 - 20 minute test time

· Specificity: 99.9%, Sensitivity: 99.7%

Commercialization

· High quality brands, marketed globally since 2007

· Sold to Public Health Clinics, POLs, Hospitals, Self Test (EU)

· Certain Distribution Partners (US): Fisher, McKesson/PSS, H. Schein, Medline

See graphics

Slide 9

Chembio DPP^® HIV and DPP^® HIV-SYP Combo Tests Addressing a Significant and Growing Need

§ DPP^® HIV-Syphilis Combo Assay

– First to market with POC HIV-Syphilis combo assay

– First to receive USAID and ANVISA (Brazil) approved

– Successfully launched in Mexico

– Global screening opportunity:

• Pregnant women

• MSM (up to 70% HIV-Syphilis co-infection)

· DPP^® HIV 1/2 Assay

– FDA-approved and CLIA-waived  (blood and oral fluid)

– Superior performance (sensitivity) vs. competitors

– Patented SampleTainer® Sample Collection System

– U.S. Launch – Q4 2014

See graphics

Slide 10

DPP^® STD - Product Development Strengthening our STD Portfolio: HIV & Syphilis

§ DPP^® HIV-Syphilis Assay (U.S. market)

– Next Generation DPP^® HIV-Syphilis Combo Assay for detection of HIV and Syphilis antibodies

– Expect clinical trials to begin Q1 2016

• Number of patients: 1200

• Duration: 6-9 months

• Cost: $1.0 - $1.5MM

Slide 11

Chembio's Dual Path Platform (DPP^®) Technology Leveraging Our Technology Platform to Enter New Markets

Three areas of Strategic Focus:

· STD Business

· Fever Portfolio

· Technology Collaborations

DPP® Technology Platform

Slide 12

Fever Diseases - A Growing Global Concern Malaria, Dengue Fever, Ebola

Malaria

· ~198 million infections/year(2013)

· ~584,000 deaths/year (2013)

Zika ?

Dengue Fever

· ~100 million infections/year (2013)

· 40% of world population at risk from Dengue (2013)

Ebola

· ~28,000 infections (2014-2015)

· ~11,000 deaths (2014-2015)

"Early diagnosis and treatment of malaria reduces disease and prevents deaths. It also contributes to reducing malaria transmission. WHO recommends that all cases of suspected malaria be confirmed using parasite-based diagnostic testing (either microscopy or rapid diagnostic test) before administering treatment" -WHO

Slide 13

DPP^® Fever - Product Development Partnering with World Leading Organizations

DPP® Fever Panel

Collaborator: Paul G. Allen Ebola Program

DPP® Zika Assay

Collaborator: Paul G. Allen Family Foundation

DPP® Malaria-Ebola

Collaborator: CDC

DPP® Dengue Fever

Collaborator: Undisclosed

DPP® Ebola

Collaborator: CDC

Slide 14

Chembio's Dual Path Platform (DPP^®) Technology Leveraging Our Technology Platform to Enter New Markets

Three areas of Strategic Focus:

· STD Business

· Fever Portfolio

· Technology Collaborations

DPP® Technology Platform

Slide 15

Established DPP^® Technology Collaborations Building Both STD and Non-STD Businesses

opTricon (Germany)

· DPP® Micro Reader designed specifically to complement Chembio's patented DPP® technology

Bio-Rad Laboratories, Inc. (NYSE: BIO)

– DPP^® used for Bio-Rad's Geenius™ HIV 1/2 Confirmatory Assay

Oswaldo Cruz Foundation (Brazil)

– Five DPP^® Products Currently Being Sold to Ministry of Health in Brazil

RVR (Malaysia)

– License, Technical Transfer, Contract Manufacturing, Distribution (planned)

Slide 16

DPP^® Technology - Collaborations Focused on Specific Product Development Opportunities

DPP® Flu Immunostatus

Collaborator: Centers for Disease Control & Prevention (contractor)

DPP® Traumatic Brain Injury

Collaborator: Perseus Science Group LLC

DPP® Cancer (Specific Form)

Collaborator: Undisclosed

DPP® Hepatitis C

Collaborator: Seeking Partner

Slide 17

Manufacturing Capabilities

United States (Chembio)

§ High volume manufacturing capabilities

– 20MM+ tests annually

§ 60,000 sq. ft. leased facilities

– Medford, NY and Holbrook, NY

§ Robust quality management system

– Full compliance with regulatory requirements (FDA, USDA, WHO, ISO)

– Expertise in manufacturing scale up, process validation and cGMP

§ Number of employees: ~155

Malaysia (RVR)

§ Completed license and technology transfer

§ Completed contract manufacturing readiness: Q4 2015

§ Initiated distribution of Chembio's products into Malaysia

§ Plan to manufacture certain Chembio-branded products

See graphics

Slide 18

Selected Financial Highlights

Years Ended (in 000's)

	December 31, 2015			December 31, 2014
Net Product Revenues	$	21,887		$	25,950
Total Revenues	$	24,255		$	27,645
Gross Margin	$	10,487		$	10,814
Loss from Operations	$	(3,554	)	$	(1,550	)
Net Loss	$	(2,387	)	$	(1,137	)
Cash  (as of end of period)	$	5,377		$	4,615

Note: took a full valuation allowance on our deferred tax asset resulting in the larger Net Loss over Loss from Operations

Slide 19

Executive Leadership Team

Executive:  John J. Sperzel III,   President &CEO

Joined Chembio: 2014

Previous Experience: 2011-2013, President and CEO of ITC.; 1987-2011 Axis-Shield, Bayer Diagnostics, Instrumentation Laboratory and Boehringer Mannheim

Executive:  Richard Larkin, CPA  Chief Financial Officer

Joined Chembio: 2003

Previous Experience: 2000-2003  CFO of Visual Technology Group; 1987-2000 CFO of Protex  International Corp.

Executive:  Sharon Klugewicz, M.S.  Chief Operating Officer

Joined Chembio: 2012

Previous Experience: 2009-2012, Sr. VP Scientific & Laboratory Services of Pall Corporation; 1991-2009 Pall Corporation

Executive:  Javan Esfandiari, M.S.  Chief Science and Technology Officer

Joined Chembio:  2000

Previous Experience: 1997-2000, Co-founder of Sinovus Biotech AB (Sweden), acquired by Chembio in 2000; 1993-1997 R&D Director On-Site Biotech

Executive:  Thomas Ippolito, VP Regulatory & Clinical Affairs

Joined Chembio: 2005

Previous Experience: 2000-2005, VP Quality & Regulatory of Biospecific Technologies Corp.; 1984-2000 United Biomedical Inc., Analytab Products Inc. and Eastern Long Island Hospital

Executive:  Michael Steele, VP Sales, Marketing and Business Development

Joined Chembio: 2012

Previous Experience: 2008-2011, VP Business Development of SeraCare Life Sciences; 1992-2008 Corautus Genetics, Life Therapeutics and Serologicals, Inc.

Executive:  Paul Lambotte, Ph.D, VP Product Development

Joined Chembio: 2014

Previous Experience: 2009 – 2014, President of PLC Inc.; 2009 – 2012 Chief Science Officer of Axxin Pty Ltd.; 2000-2009, VP of R&D and Business Development of Quidel, Inc.

Slide 20

2015/2016 Milestones – Achieved

§ Signed agreement to develop DPP^® Brain Injury Assay

– Perseus Science; January 2015

§ Received ANVISA approval for DPP^® HIV-Syphilis Assay

– Brazil; February 2015

§ Initiated field testing of DPP^® Ebola Assay in West Africa

– CDC; June 2015

§ Awarded Grant to Develop Multiplex Test for Fever Diseases

– Paul G. Allen Ebola Program; October 2015

§ Signed agreement to launch the DPP® Micro Reader

– opTricon; October 2015

§ Acquired full rights to SURE CHECK^® HIV 1/2 Assay

– SDS; signed January 2015 to be effective June 1, 2016

§ Awarded Grant to Develop DPP^® Zika Assay

– Paul G. Allen Family Foundation; February 2016

Slide 21

Investment Highlights

§ A global leader in point-of-care (POC) infectious disease

– Sales in 40+ countries, including United States

§ Revenue growth

– 8% CAGR over last five years (2010-2015)

§ Groundbreaking DPP^® technology platform

– Superior sensitivity and specificity vs lateral flow technology

– Multiple tests from a single oral fluid or blood sample

§ Robust pipeline of new DPP^® POC assays in development

– DPP^® HIV-Syphilis Combination Assay (U.S. version)

– DPP^® Fever Assays (Malaria, Dengue , Zika, Chikungunya, Ebola, Lassa, Marburg)

– DPP^® Technology Collaboration (Traumatic Brain Injury, Cancer Micro Reader)

§ Multiple high-value collaborations

– Paul G. Allen Ebola Program: Fever Panel

– Paul G. Allen Family Foundation: Zika

– Centers for Disease Control & Prevention (CDC): Malaria, Ebola, Flu Immunostatus